Sheffield

Horizontal Tabs

Treatment Modalities 
Radiotherapy
Small Molecules
Surgery
Immunotherapy
Facilities/Translational Research 
Phase 1 Capability
  • Phase 1 population: adult solid tumours
  • First-in-Man studies
  • Multi-centre Phase 1 studies
  • Centre specific translational research interest: Bone oncology, vascular biology, lung cancer biology

Mechanisms studied:

  • Bisphosphonates
  • RANK ligand inhibitors
  • CD56 targeted antibody
  • Taxanes
  • Diaphorase inhibitor
  • TKI inhibitors
Technology/equipment available within the centre
  • MRI, CT
  • DNA sequencing (Applied Biosystems 3730 capillary sequencer)
  • SNP genotyping Quantitative RT-PCR (384-well Applied Biosystems 7900HT platform)
  • Mutation detection (Transgenomic WAVE dHPLC)
  • High-throughput robotic screening lab (Genetix Q-bot and MegaPix)
  • Expression and SNP analysis (Affymetrix Genechip hybridisation system)
  • Flow cytometry (Becton Dickenson FACSort and FACSAria)
  • SELDI and MALDI-TOF mass spectrometry
  • Core hisopathology facilities including tissue microarrays
Other Facilities
  • Purpose-built cancer clinical trials centre
  • Hospital CRF
  • BioBank
Sample collection
  • Tissue Banking Activities: Dedicated biobank, Prof FC Hamdy
  • Other equipment/ facilities not on site: PET scanning

 

ECMC funding provides infrastructure support for early phase and translational research.  From the ECMC Sheffield portfolio, the following trials have been carried out.

 
Trial activity between 2012-2015:

 

Trial by disease type between 2012-2015: